2023 World Conference on Lung Cancer (Posters)-EP06.04. Challenge to Detect CTC-derived EGFR Mutation of Non-small Cell Lung Carcinoma by Unique Blood-Filtration Device

EP06.04. Challenge to Detect CTC-derived EGFR Mutation of Non-small Cell Lung Carcinoma by Unique Blood-Filtration Device - PDF(Abstract)

Back to course

Pdf Summary

Liquid biopsy has become an important diagnostic test for patients with lung cancer in order to detect Epidermal growth factor receptor (EGFR) mutations. However, the sensitivity of liquid biopsy is not high. In this study, researchers aimed to develop a new technology with a higher sensitivity than conventional methods.<br /><br />Blood samples were obtained from surgically resected lung tissue, including pulmonary malignant tumors. Circulating tumor cells (CTC) were isolated using a unique blood-filtration device developed by the researchers. The CTC samples were then stained and counted under a microscope. DNA was extracted from the CTC samples and EGFR status was investigated using digital PCR. The EGFR status of the pulmonary tumor tissue was also investigated using the cobas EGFR mutation test v2.0.<br /><br />Results showed that CTC were morphologically detected in 11 out of 12 cases. EGFR mutation was detected in 6 blood samples and 8 tumor tissue samples. Six cases showed a positive mutation in both CTC and tissue, while 4 cases showed a negative mutation in both CTC and tissue. Interestingly, there were 2 cases where the mutation was detected in the tissue but not in the CTC.<br /><br />The sensitivity of the new blood-filtration device in detecting EGFR mutations was found to be 0.75, with a specificity of 1.00, a positive predictive value of 1.00, and a negative predictive value of 0.67.<br /><br />In conclusion, the unique blood-filtration device was effective in isolating CTC and investigating EGFR status. However, further experiments are needed to better understand its performance. The development of this new technology has the potential to improve the sensitivity of liquid-based biomarkers in the detection of EGFR mutations in non-small cell lung carcinoma.

Asset Subtitle

Hitoshi Dejima

Meta Tag

Speaker Hitoshi Dejima

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

liquid biopsy

lung cancer

EGFR mutations

sensitivity

new technology

blood samples

CTC

blood-filtration device

EGFR status

non-small cell lung carcinoma